Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas
Open Access
- 1 April 2019
- journal article
- research article
- Published by Elsevier in Human Pathology
- Vol. 86, 66-75
Abstract
No abstract availableKeywords
Funding Information
- Finnish Awarded Special State Subsidy EVO (TYH 2014203)
- Finnish cancer foundation (4703666)
This publication has 31 references indexed in Scilit:
- Mapping of Succinate Dehydrogenase Losses in 2258 Epithelial NeoplasmsApplied Immunohistochemistry & Molecular Morphology, 2014
- Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumorsEndocrine-Related Cancer, 2012
- Somatostatin Receptor Subtype 2A Immunohistochemistry Using a New Monoclonal Antibody Selects Tumors Suitable for In Vivo Somatostatin Receptor TargetingAmerican Journal of Surgical Pathology, 2012
- Radiopeptide Imaging and Therapy in EuropeJournal of Nuclear Medicine, 2011
- Malignant pheochromocytoma: a reviewThe American Journal of Surgery, 2011
- Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumoursClinical Endocrinology, 2007
- Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphyLaboratory Investigation, 2007
- Somatostatin Receptor Subtypes in Human Pheochromocytoma: Subcellular Expression Pattern and Functional Relevance for Octreotide ScintigraphyThe Journal of Clinical Endocrinology & Metabolism, 2003
- DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometalsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Peptide Receptors as Molecular Targets for Cancer Diagnosis and TherapyEndocrine Reviews, 2003